Medical/Pharmaceuticals

Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...

2023-02-27 21:00 2446

The first case of COVID pregnant mother in Guangzhou was successfully delivered by cesarean section and the newborn was in good condition; doctors treat pregnant COVID-19 patient Under Quarantine Protection

The First Case of Successful Delivery of Patient with COVID-19 in Guangzhou GUANGZHOU, China, Feb. 27, 2023 /PRNewswire/ -- "Mother and daughter are safe, the child is 2.85 kilograms." In the early morning ofNovember 1st, director of the Department of Obstetrics and Gynecology, Liang Huichao said...

2023-02-27 17:18 2562

Singleron Biotechnologies and Macrogen Europe announce a strategic alliance

Singleron Biotechnologies and Macrogen Europe are happy to announce their collaboration to combine their strengths to provide first-class single cell multi-omics sequencing solutions. COLOGNE, Germany, Feb. 27, 2023 /PRNewswire/ -- Singleron Biotechnologies , a front-runn...

2023-02-27 16:00 2670

Distinguished Acupuncturist in China, Zhaohui Zhang Publishes Paper on Neuromodulation as the Corresponding Author

NANJING, China, Feb. 26, 2023 /PRNewswire/ -- At the beginning of February 2023, Zhaohui Zhang from Jiangsu Provincial People's Hospital received a job offer from the editorial department after the Chinese Lantern Festival. As the corresponding author, he wrote the paper "Auricular Vagal Nerve Sti...

2023-02-27 09:51 2373

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

HAIKOU, China, Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveMonday, March 6, 2023, with trading to begin on a split-adjusted basis ...

2023-02-25 05:05 6465

Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib

* With the efficacy comparable to rival drugs, Oscotec plans to advance to the next step, leaving the door open for partnership PANGYO, South Korea, Feb. 24, 2023 /PRNewswire/ -- Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidop...

2023-02-24 22:00 4563

Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform

SUZHOU, China, Feb. 24, 2023 /PRNewswire/ -- On February 20, 2023, Porton Advanced Solutions Ltd. (Porton Advanced) and Yinjia (Shanghai) Biosciences Co., Ltd. (Yinjia Biosciences) announced a strategic partnership in developing core protein raw materials for cell and gene therapy (CGT) and test ...

2023-02-24 20:00 2673

Dr. Lilly Xu Named President of Shanghai ChemPartner

SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner. Dr. Xu is a seasoned manager with a strong portfolio ...

2023-02-24 05:53 3798

Qilian Received Notification of Deficiency from Nasdaq Related to not timely Filing of Annual Report Form 20-F

JIUQUAN, China, Feb. 23, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced it has received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on Feb...

2023-02-24 05:30 4333

Zhongchao Inc. Renews Partnership with Johnson & Johnson (China)

SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the renewal of the partnership between Zhongchao Medical Technol...

2023-02-23 21:00 4651

Rayence unveils the first X-ray detector technology utilizing SPAD technology

* Presenting the cutting-edge detector technology, 'SPAD-GS', which is 2.5 times more sensitive to X-rays and 4 times faster than ever * Implemented the world's first X-ray detector using the 'SPAD', digital pixel technology capable of single-photon detection * Being announced and drawing at...

2023-02-23 21:00 3791

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class C...

2023-02-23 13:01 2866

Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration

* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea®  Biosimilar (ALT-L9) clinical development and licensing-out discussions. * Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, So...

2023-02-22 22:00 3667

150th Anniversary of Dr. Hansen's Discovery of M. leprae Is Opportunity to Examine Past, Present and Future of Leprosy

TOKYO, Feb. 22, 2023 /PRNewswire/ -- The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will hold an event inBergen on Feb. 28, 2023, to mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus,M. leprae, in 1873. On the same da...

2023-02-22 22:00 2879

GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate

PISCATAWAY, N.J. and SINGAPORE, Feb. 22, 2023 /PRNewswire/ -- GenScript ProBio, a leading global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of  messenger RNA (mRNA) therapeu...

2023-02-22 21:00 3689

AnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up Study

NEW YORK, Feb. 22, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...

2023-02-22 20:30 3097

Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA

SHENZHEN, China, Feb. 22, 2023 /PRNewswire/ -- Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials. FP002 is a humanized anti-CD...

2023-02-22 20:17 2667

Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON

WUHAN, China and SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in the Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON) inChina. It marks the completion of patient enr...

2023-02-21 21:30 3688

Meihua International Medical Technologies Co., Ltd. Enters Into Cooperation Agreements with Hainan's Qionghai City and Hainan Free Trade Port Boao Hope City to Build Technology Park and Medical Research and Development Center

YANGZHOU, China, Feb. 21, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company, vi...

2023-02-21 20:30 3781

NMPA accepted the registration applications for Uro-G and Uro-3500

SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...

2023-02-21 17:46 2742
1 ... 194195196197198199200 ... 263